Table 4.
1 Week Post-Commencement of MS/Mimotopic Peptide Therapy
| Epitope-Specific Serum IgE Signal: | |||
|
| |||
| ADARM | Pre-Rx | 422 | |
| ADARM | Post-Rx | -93 | |
| HSYQE | Pre-Rx | 809 | |
| HSYQE | Post-Rx | -309 | |
| KTGQF | Pre-Rx | 333 | |
| KTGQF | Post-Rx | -1,353 | |
|
| |||
| Epitope-Specific Serum (kappa + lambda) Signal: | |||
|
| |||
| ADARM | Pre-Rx | 673 | |
| ADARM | Post-Rx | -4,383 | |
| HSYQE | Pre-Rx | 1,458 | |
| HSYQE | Post-Rx | -4,227 | |
| KTGQF | Pre-Rx | 511 | |
| KTGQF | Post-Rx | -4,383 | |
|
| |||
| ADARM before Treatment: | ADARM after Treatment: | ||
|
| |||
| KL | 16,833,501 | KL | -109,577,976 |
| E/KL | 0.000025 | E/KL | -0.000001 |
| x 1 million | 25 | x 1 million | -1 |
|
| |||
| HSYQE before Treatment: | HSYQE after Treatment: | ||
|
| |||
| KL | 36,459,750 | KL | -3,645,975 |
| E/KL | 0.554734 | E/KL | -0.073074 |
| x 1 million | 554,734 | x 1 million | -73,074 |
|
| |||
| KTGQF before Treatment: | KTGQF after Treatment: | ||
|
| |||
| KL | 12,762,509 | KL | -4,383 |
| E/KL | 0.000026 | E/KL | -33,823,947 |
| x 1 million | 26 | x 1 million | -33,823,947,401,145 |
MS activity factor (MSAF) 1 week after commencing therapy is displayed. The MSAF method, IgE/(kappa + lambda, is a numerical formula used to diagnose and monitor multiple sclerosis. The MSAF process distinguishes and integrates: (1) IgE binding onto critically-spaced myelin epitopes; (2) specific IgE targeting and affixation by enzyme-releasing mast cells; and (3) the released enzymes’ degradation of central nervous system tissues. The MSAF, ELISA-based method for distinguishing and quantifying the MS process entails: (a) measurement of specific IgE and non-IgE (kappa + lambda) micro-well, chemiluminescence signals; (b) subtracting background point values from antigenic, peptide-coated well values; (c) multiplying the (kappa + lambda) signals by 25,000 to adjust for required serum dilution; (c) dividing IgE point values by their corresponding (kappa + lambda) values; and (d) multiplying the result by 1,000,000 and seeking the attainment of positive numbers. Derived, positive results indicate the presence of active IgE dimer points and myelin-dimer-generated pathology. Negative values indicate the opposite. The one-week follow-up MSAF analysis of the study showed ADARM-negative, HSYQE-negative and KTGQF-negative results as compared to the positive pre-treatment serum analysis, thus indicating anti-myelin autoantibody neutralization by the administered mimotopic peptides. The absolute ratio quantities, positive or negative, were not disease-severity relevant. Formula to Estimate MS Activity Factor (MSAF) => Net IgE/Net KL x 1,000,000. KL = specific (kappa + lambda) signal x 25,000 (Compensates for 1/25,000 serum dilution).